In Vivo Sustained Release of Peptide Vaccine Mediated by Dendritic Mesoporous Silica Nanocarriers

Mesoporous silica nanoparticles have drawn increasing attention as promising candidates in vaccine delivery. Previous studies evaluating silica-based vaccine delivery systems concentrated largely on macromolecular antigens, such as inactivated whole viruses. In this study, we synthesized dendritic m...

Full description

Bibliographic Details
Main Authors: Weiteng An, Sira Defaus, David Andreu, Pilar Rivera-Gil
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.684612/full
id doaj-2e241b69e06e43baac04d4bb0c52ff54
record_format Article
spelling doaj-2e241b69e06e43baac04d4bb0c52ff542021-06-16T17:07:34ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-06-011210.3389/fimmu.2021.684612684612In Vivo Sustained Release of Peptide Vaccine Mediated by Dendritic Mesoporous Silica NanocarriersWeiteng An0Sira Defaus1David Andreu2Pilar Rivera-Gil3Integrative Biomedical Materials and Nanomedicine Laboratory, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, SpainProteomics and Protein Chemistry Unit, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, SpainProteomics and Protein Chemistry Unit, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, SpainIntegrative Biomedical Materials and Nanomedicine Laboratory, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, SpainMesoporous silica nanoparticles have drawn increasing attention as promising candidates in vaccine delivery. Previous studies evaluating silica-based vaccine delivery systems concentrated largely on macromolecular antigens, such as inactivated whole viruses. In this study, we synthesized dendritic mesoporous silica nanoparticles (DMSNs), and we evaluated their effectiveness as delivery platforms for peptide-based subunit vaccines. We encapsulated and tested in vivo an earlier reported foot-and-mouth disease virus (FMDV) peptide vaccine (B2T). The B2T@DMSNs formulation contained the peptide vaccine and the DMSNs without further need of other compounds neither adjuvants nor emulsions. We measured in vitro a sustained release up to 930 h. B2T@DMSNs-57 and B2T@DMSNs-156 released 23.7% (135 µg) and 22.8% (132 µg) of the total B2T. The formation of a corona of serum proteins around the DMSNs increased the B2T release up to 61% (348 µg/mg) and 80% (464 µg/mg) for B2T@DMSNs-57 and B2T@DMSNs-156. In vitro results point out to a longer sustained release, assisted by the formation of a protein corona around DMSNs, compared to the reference formulation (i.e., B2T emulsified in Montanide). We further confirmed in vivo immunogenicity of B2T@DMSNs in a particle size-dependent manner. Since B2T@DMSNs elicited specific immune responses in mice with high IgG production like the reference B2T@Montanide™, self-adjuvant properties of the DMSNs could be ascribed. Our results display DMSNs as efficacious nanocarriers for peptide-based vaccine administration.https://www.frontiersin.org/articles/10.3389/fimmu.2021.684612/fulldendritic mesoporous silica nanoparticlespeptide vaccinessustained and controlled releasefoot-and-mouth disease virusnanovaccineimmunogenicity
collection DOAJ
language English
format Article
sources DOAJ
author Weiteng An
Sira Defaus
David Andreu
Pilar Rivera-Gil
spellingShingle Weiteng An
Sira Defaus
David Andreu
Pilar Rivera-Gil
In Vivo Sustained Release of Peptide Vaccine Mediated by Dendritic Mesoporous Silica Nanocarriers
Frontiers in Immunology
dendritic mesoporous silica nanoparticles
peptide vaccines
sustained and controlled release
foot-and-mouth disease virus
nanovaccine
immunogenicity
author_facet Weiteng An
Sira Defaus
David Andreu
Pilar Rivera-Gil
author_sort Weiteng An
title In Vivo Sustained Release of Peptide Vaccine Mediated by Dendritic Mesoporous Silica Nanocarriers
title_short In Vivo Sustained Release of Peptide Vaccine Mediated by Dendritic Mesoporous Silica Nanocarriers
title_full In Vivo Sustained Release of Peptide Vaccine Mediated by Dendritic Mesoporous Silica Nanocarriers
title_fullStr In Vivo Sustained Release of Peptide Vaccine Mediated by Dendritic Mesoporous Silica Nanocarriers
title_full_unstemmed In Vivo Sustained Release of Peptide Vaccine Mediated by Dendritic Mesoporous Silica Nanocarriers
title_sort in vivo sustained release of peptide vaccine mediated by dendritic mesoporous silica nanocarriers
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2021-06-01
description Mesoporous silica nanoparticles have drawn increasing attention as promising candidates in vaccine delivery. Previous studies evaluating silica-based vaccine delivery systems concentrated largely on macromolecular antigens, such as inactivated whole viruses. In this study, we synthesized dendritic mesoporous silica nanoparticles (DMSNs), and we evaluated their effectiveness as delivery platforms for peptide-based subunit vaccines. We encapsulated and tested in vivo an earlier reported foot-and-mouth disease virus (FMDV) peptide vaccine (B2T). The B2T@DMSNs formulation contained the peptide vaccine and the DMSNs without further need of other compounds neither adjuvants nor emulsions. We measured in vitro a sustained release up to 930 h. B2T@DMSNs-57 and B2T@DMSNs-156 released 23.7% (135 µg) and 22.8% (132 µg) of the total B2T. The formation of a corona of serum proteins around the DMSNs increased the B2T release up to 61% (348 µg/mg) and 80% (464 µg/mg) for B2T@DMSNs-57 and B2T@DMSNs-156. In vitro results point out to a longer sustained release, assisted by the formation of a protein corona around DMSNs, compared to the reference formulation (i.e., B2T emulsified in Montanide). We further confirmed in vivo immunogenicity of B2T@DMSNs in a particle size-dependent manner. Since B2T@DMSNs elicited specific immune responses in mice with high IgG production like the reference B2T@Montanide™, self-adjuvant properties of the DMSNs could be ascribed. Our results display DMSNs as efficacious nanocarriers for peptide-based vaccine administration.
topic dendritic mesoporous silica nanoparticles
peptide vaccines
sustained and controlled release
foot-and-mouth disease virus
nanovaccine
immunogenicity
url https://www.frontiersin.org/articles/10.3389/fimmu.2021.684612/full
work_keys_str_mv AT weitengan invivosustainedreleaseofpeptidevaccinemediatedbydendriticmesoporoussilicananocarriers
AT siradefaus invivosustainedreleaseofpeptidevaccinemediatedbydendriticmesoporoussilicananocarriers
AT davidandreu invivosustainedreleaseofpeptidevaccinemediatedbydendriticmesoporoussilicananocarriers
AT pilarriveragil invivosustainedreleaseofpeptidevaccinemediatedbydendriticmesoporoussilicananocarriers
_version_ 1721374932733001728